William Blair Issues Negative Outlook for Certara Earnings

Certara, Inc. (NASDAQ:CERT) – William Blair decreased their Q3 2025 earnings per share (EPS) estimates for shares of Certara in a report released on Monday, April 14th. William Blair analyst M. Smock now anticipates that the company will post earnings per share of $0.07 for the quarter, down from their previous forecast of $0.09. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Certara’s current full-year earnings is $0.28 per share. William Blair also issued estimates for Certara’s Q3 2026 earnings at $0.09 EPS and Q4 2026 earnings at $0.08 EPS.

Several other analysts have also recently weighed in on CERT. TD Cowen initiated coverage on Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price target for the company. KeyCorp boosted their price target on shares of Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday. Barclays lowered their price objective on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Robert W. Baird upped their target price on shares of Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday, April 11th. Finally, Stephens restated an “overweight” rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Certara currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.17.

Certara Trading Down 2.5 %

Certara stock opened at $13.53 on Tuesday. The stock has a market cap of $2.18 billion, a P/E ratio of -67.65, a PEG ratio of 9.29 and a beta of 1.64. Certara has a fifty-two week low of $8.64 and a fifty-two week high of $17.94. The firm’s fifty day moving average price is $11.62 and its 200-day moving average price is $11.43. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Hedge Funds Weigh In On Certara

A number of large investors have recently added to or reduced their stakes in CERT. Versant Capital Management Inc grew its stake in shares of Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock valued at $27,000 after buying an additional 1,866 shares during the last quarter. Venturi Wealth Management LLC grew its position in Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after acquiring an additional 2,509 shares during the last quarter. Wells Fargo & Company MN increased its stake in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares during the period. Johnson Financial Group Inc. purchased a new position in Certara in the 4th quarter worth approximately $47,000. Finally, Blue Trust Inc. lifted its position in Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after purchasing an additional 822 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.